JP2009507790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009507790A5 JP2009507790A5 JP2008529133A JP2008529133A JP2009507790A5 JP 2009507790 A5 JP2009507790 A5 JP 2009507790A5 JP 2008529133 A JP2008529133 A JP 2008529133A JP 2008529133 A JP2008529133 A JP 2008529133A JP 2009507790 A5 JP2009507790 A5 JP 2009507790A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- alkyl
- compound
- compound according
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 55
- 125000001931 aliphatic group Chemical group 0.000 claims 47
- 125000000217 alkyl group Chemical group 0.000 claims 34
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 9
- 101100180319 Mus musculus Itk gene Proteins 0.000 claims 8
- 125000002723 alicyclic group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 239000012472 biological sample Substances 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001301 oxygen Chemical group 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 108091000080 Phosphotransferase Proteins 0.000 claims 4
- 125000001118 alkylidene group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 102000020233 phosphotransferase Human genes 0.000 claims 4
- 229910052717 sulfur Chemical group 0.000 claims 4
- 239000011593 sulfur Chemical group 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 206010039083 rhinitis Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 2
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 108060006633 protein kinase Proteins 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 208000035939 Alveolitis allergic Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000027445 Farmer Lung Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021388 Sezary disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 201000009151 chronic rhinitis Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000005888 cyclopropanation reaction Methods 0.000 claims 1
- 238000005906 dihydroxylation reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 208000022195 farmer lung disease Diseases 0.000 claims 1
- 125000006161 haloaliphatic group Chemical group 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000009240 nasopharyngitis Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims 1
- -1 —O (Ph) Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71245705P | 2005-08-29 | 2005-08-29 | |
| US60/712,457 | 2005-08-29 | ||
| PCT/US2006/033282 WO2007027528A2 (en) | 2005-08-29 | 2006-08-25 | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-.receptor tyrosine kinases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012138966A Division JP2012184260A (ja) | 2005-08-29 | 2012-06-20 | 非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009507790A JP2009507790A (ja) | 2009-02-26 |
| JP2009507790A5 true JP2009507790A5 (enExample) | 2009-07-16 |
| JP5112317B2 JP5112317B2 (ja) | 2013-01-09 |
Family
ID=37565557
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529133A Expired - Fee Related JP5112317B2 (ja) | 2005-08-29 | 2006-08-25 | 非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン |
| JP2012138966A Withdrawn JP2012184260A (ja) | 2005-08-29 | 2012-06-20 | 非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012138966A Withdrawn JP2012184260A (ja) | 2005-08-29 | 2012-06-20 | 非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7786120B2 (enExample) |
| EP (1) | EP1919905B1 (enExample) |
| JP (2) | JP5112317B2 (enExample) |
| CN (1) | CN101291926A (enExample) |
| AT (1) | ATE499362T1 (enExample) |
| AU (1) | AU2006285145A1 (enExample) |
| CA (1) | CA2620631A1 (enExample) |
| DE (1) | DE602006020293D1 (enExample) |
| ES (1) | ES2361338T3 (enExample) |
| WO (1) | WO2007027528A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007027729A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
| AU2006285038A1 (en) * | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases |
| JP5587193B2 (ja) | 2007-10-23 | 2014-09-10 | エフ．ホフマン−ラ ロシュ アーゲー | 新規なキナーゼ阻害剤 |
| US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| PE20100851A1 (es) | 2008-06-24 | 2011-01-31 | Hoffmann La Roche | PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk |
| PL2300459T3 (pl) | 2008-07-02 | 2013-10-31 | Hoffmann La Roche | Nowe fenylopirazynony jako inhibitory kinazy |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| WO2013153539A1 (en) | 2012-04-13 | 2013-10-17 | Glenmark Pharmaceuticals S.A. | Tricyclic compounds as tec kinase inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5308854A (en) | 1990-06-18 | 1994-05-03 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
| NZ238576A (en) * | 1990-06-18 | 1994-12-22 | Merck & Co Inc | Pyridinone derivatives, preparation and pharmaceutical compositions thereof |
| KR100196559B1 (ko) | 1990-06-19 | 1999-06-15 | 기따사또 이찌로 | 안지오텐신ii 길항작용을 함유하는 피리딘 유도체 |
| IL99731A0 (en) * | 1990-10-18 | 1992-08-18 | Merck & Co Inc | Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them |
| DE4221583A1 (de) | 1991-11-12 | 1993-05-13 | Bayer Ag | Substituierte biphenylpyridone |
| US5290941A (en) | 1992-10-14 | 1994-03-01 | Merck & Co., Inc. | Facile condensation of methylbenzoxazoles with aromatic aldehydes |
| DE4314964A1 (de) | 1993-05-06 | 1994-11-10 | Bayer Ag | Pyridinylmethyl-substiutierte Pyridine und Pyridone |
| DE4314963A1 (de) | 1993-05-06 | 1994-11-10 | Bayer Ag | Substituierte Pyridine und 2-Oxo-1,2-dihydropyridine |
| DE4316077A1 (de) | 1993-05-13 | 1994-11-17 | Bayer Ag | Substituierte Mono- und Bihydridylmethylpyridone |
| US6979695B2 (en) | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| CZ20003978A3 (cs) | 1998-04-27 | 2001-09-12 | Centre National De La Recherche Scientifique | Deriváty 3-(amino- nebo aminoalkyl) pyridinonu a jejich použití |
| US6774138B2 (en) | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
| IL150650A0 (en) | 2000-01-20 | 2003-02-12 | Eisai Co Ltd | Piperidine derivatives and pharmaceutical compositions containing the same |
| WO2001096308A1 (en) * | 2000-06-12 | 2001-12-20 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| ATE319706T1 (de) * | 2000-09-19 | 2006-03-15 | Centre Nat Rech Scient | Pyridinon und pyridinethion-derivate mit hiv- hemmenden eigenschaften |
| EP1343763A1 (en) | 2000-11-20 | 2003-09-17 | Bristol-Myers Squibb Company | Pyrodone derivatives as ap2 inhibitors |
| DE60139506D1 (de) | 2000-12-28 | 2009-09-17 | Shionogi & Co | 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor |
| CA2442428A1 (en) | 2001-03-28 | 2002-10-10 | Mark D. Wittman | Novel tyrosine kinase inhibitors |
| JP2002371078A (ja) * | 2001-06-12 | 2002-12-26 | Sankyo Co Ltd | キノリン誘導体及びキノロン誘導体 |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| AP1822A (en) * | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| JP4208512B2 (ja) | 2002-07-23 | 2009-01-14 | 株式会社クラレ | ５−（２’−ピリジル）−２−ピリドン誘導体の製造方法 |
| AU2003274025A1 (en) | 2002-10-17 | 2004-05-04 | Syngenta Participations Ag | Pyridine derivatives useful as herbicides |
| WO2004035563A1 (en) | 2002-10-17 | 2004-04-29 | Syngenta Participations Ag | 3-heterocyclylpyridine derivatives useful as herbicides |
| CA2506741A1 (en) | 2002-11-27 | 2004-06-17 | Artesian Therapeutics, Inc. | Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure |
| AU2003300297A1 (en) | 2002-12-23 | 2004-07-22 | Artesian Therapeutics, Inc. | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST Beta-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE |
| WO2005007159A1 (en) | 2003-07-14 | 2005-01-27 | The General Hospital Corporation | Methods for treating vascular diseases |
| CL2004002050A1 (es) * | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| MX2007001399A (es) | 2004-08-02 | 2007-04-18 | Osi Pharm Inc | Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas. |
| MX2007007330A (es) * | 2004-12-16 | 2007-10-04 | Vertex Pharma | Piridonas de utilidad como inhibidores de quinasas . |
| AU2006223409B2 (en) | 2005-03-10 | 2011-07-21 | Gilead Connecticut, Inc. | Certain substituted amides, method of making, and method of use thereof |
| AU2006285038A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases |
| WO2007027729A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
-
2006
- 2006-08-25 JP JP2008529133A patent/JP5112317B2/ja not_active Expired - Fee Related
- 2006-08-25 AU AU2006285145A patent/AU2006285145A1/en not_active Abandoned
- 2006-08-25 EP EP06813771A patent/EP1919905B1/en not_active Not-in-force
- 2006-08-25 DE DE602006020293T patent/DE602006020293D1/de active Active
- 2006-08-25 US US11/510,126 patent/US7786120B2/en not_active Expired - Fee Related
- 2006-08-25 AT AT06813771T patent/ATE499362T1/de not_active IP Right Cessation
- 2006-08-25 CN CNA2006800393748A patent/CN101291926A/zh active Pending
- 2006-08-25 CA CA002620631A patent/CA2620631A1/en not_active Abandoned
- 2006-08-25 ES ES06813771T patent/ES2361338T3/es active Active
- 2006-08-25 WO PCT/US2006/033282 patent/WO2007027528A2/en not_active Ceased
-
2012
- 2012-06-20 JP JP2012138966A patent/JP2012184260A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009507792A5 (enExample) | ||
| JP2009506123A5 (enExample) | ||
| AU2022200946B2 (en) | Modulators of the integrated stress pathway | |
| CN106518924B (zh) | 用于治疗nk-1受体相关疾病的取代的4-苯基吡啶 | |
| JP7703518B2 (ja) | 抗ウイルスプロドラッグ及びその製剤 | |
| TWI702222B (zh) | （ｒ）-及（ｓ）-１-（３-（３-ｎ，ｎ-二甲基胺基羰基）苯氧基-４-硝苯基）-１-乙基-ｎ，ｎ’-雙（伸乙基）胺基磷酸酯、組合物及其使用及製備方法 | |
| TWI706958B (zh) | 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法 | |
| US9649309B2 (en) | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity | |
| ES2617763T3 (es) | Sal de besilato de un inhibidor de BTK | |
| CA2903285C (en) | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2003507456A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| JP2023524970A5 (enExample) | ||
| CN115843272B (zh) | Nek7激酶的抑制剂 | |
| IL277146B2 (en) | Amino acid compounds and methods of use | |
| JP2015520143A5 (enExample) | ||
| JP2004509118A5 (enExample) | ||
| JP2012530703A5 (enExample) | ||
| JP2011006480A5 (enExample) | ||
| RU2016110021A (ru) | Алкиниловые спирты и способы их применения | |
| JP2019527718A5 (enExample) | ||
| JP2014521652A5 (enExample) | ||
| JP2011500539A5 (enExample) | ||
| JP2015509098A5 (enExample) | ||
| JP2009528991A5 (enExample) |